KLRC1 and cancer: These results suggest that metabolic drugs such as metformin and hydroxychloroquine, which are being investigated for their use as anti-cancer therapies, may allow NKG2A-educated NK cells to retain cytotoxic function while simultaneously inhibiting cancer cell function.